Company news
Marijuana Inc. (OTC:MAJI) news
Marijuana Inc. news releases on 6ix. Latest, Sep 29, 2026: NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair…
Press releases & updates
NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology
September 29, 2026
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
September 25, 2026
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion
August 6, 2026
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
August 5, 2026
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
July 28, 2026
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
July 22, 2026
NexTel Medical Corp. Announces Strategic Exit from Cannabis and CBD Sector to Pivot 100% to Wellness and Healthcare
July 8, 2026
NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
June 17, 2026
NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University
June 9, 2026
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
June 2, 2026
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
May 11, 2026
NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test
April 7, 2026
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
March 16, 2026
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
March 5, 2026
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
February 10, 2026
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
December 11, 2025
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
December 5, 2025
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
December 2, 2025
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
November 17, 2025
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
November 4, 2025
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
October 28, 2025
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
September 29, 2025
Exousia Pro Reports Positive Outcome in Legal Proceeding
September 26, 2025
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
September 10, 2025
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
September 8, 2025
Exousia Pro Creates New Subdivisions
September 3, 2025
Exousia Pro Files Reg A.
June 25, 2025
Exousia Pro Expands its Scientific Advisory Board
June 18, 2025
Exousia Pro Will Launch a Web Series with Our New Consultant
April 30, 2025
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
April 29, 2025
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
April 20, 2025
Exousia Pro Offers Guidance on New Subdivisions
April 16, 2025
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
April 7, 2025
Exousia Pro Issues Update on Name Change
April 2, 2025
Exousia Pro Has Appointed Matthew Dwyer As Its New President
April 1, 2025
Exousia Pro Issues and Update on its FDA Orphan Drug Status
March 31, 2025
Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
March 24, 2025
Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market
January 5, 2025
GRN Holding Corporation Announces Rebranding to Marijuana Inc. Under the Leadership of the “Henry Ford of the Marijuana Industry,” Donald Steinberg
June 25, 2024
GRN Holding Corp Announces Joint Venture With One World Legends on Global Distribution of Cannabis
August 14, 2023
GRN Holding Corporation Successfully Completes Merger with Marijuana Inc., Creating a Leading Force in the Cannabis Industry
May 22, 2023
GRN Holding Corporation Continues To Execute Business Plan With Acquisition Of California Corporation With Multiple Cannabis Licenses
April 19, 2023
GRN Holdings Corporation Signs Letter of Intent for Corporate Restructuring
January 17, 2023
GRN Holdings Corporation, Inc. (OTC: GRNF) Announces Name Change to Marijuana Inc., New Management and Business Model
August 5, 2022